Prof Elena Baranova MD PhD
European Expert “Genomics for Health”for the European Commission, EU.
President of the European Instritute of Personalised Prevention & Health, Monaco.

Highest French University DiplomaHabilitation à Diriger des Recherches (HDR) Cellular & Molecular Genetics (France)
(Spécialisation : New genetics –pharmacogenomics, nutrigenetics, etc..)
1999
PhD : Cellular & Molecular Genetics (polymorphic effects of metabolic genes. Practical applications)
(France)                                                                                                                                                      
1999 Diploma in Genetic Epidemiology                                                                               
European Mediterranean School of Medical Statistics and Clinical Epidemiology.
(Harvard University Program)                                                                                                                                         
1999Diploma in Clinical Epidemiology European Mediterranean School of Medical Statistics and Clinical Epidemiology 
(Harvard University Program)
1998Specialisation in infectious diseases  (St.Peterburg, Russia)                                                                                       
1992 MD (St Petersburg, Russia)                                                                                                                                               
1990Diploma in biocybernetic medicine & GDV techniques                                                                                              
2005Training in psychosomatic disorders & strategic therapy                                                                                 
2000-2002 PROFESSIONALPresident of the European Institute of Personalised Prevention                                                          
since March 2005European Expert for Project Evaluation
Genomics, Life Sciences, Biotechnology  for Health
Sixth EU Framework Programme                                                                                                   
since December 2003
(expert number: EX2002B003566)
Participation in project evaluation and determination of the European strategies for “Food safety & quality” (priority 5) and Marie-Curie Actions.                                                                                           

Consultant-expert in Genomics for Health & Biotechnology 
since 2002
“Gènes-Environnement” – Clermont-Ferrand/ Paris – France.
Counselling in setting & development of projects in molecular biology, October
new genetics and personalised medicine/prevention / anti-aging fields.
Expertises for result interpretation of genetic tests

2011- "Genomics - The Art of Wellbeing. New Trends and Applications."

Anti-ageing medicine represents an important field of application of genomics usage in relation to early presymptomatic personalized prevention through effective genomic and epigenetic programs. However, despite the significant increase of the number of genetic testing companies, only less than 9 % of all available genetic services in the world provide personalised genomic expertise for prevention purposes.
This presentation is based on 15 years of research, clinical and teaching experience of genetics/genomic personalised medicine and highlights:

• Main mistakes of understanding of genomic usage for prevention and anti-ageing medicine. This point reflects significant medical, ethical and psychological problems in the modern society, including the non-understanding of Evidence Based Medicine (EBM) criteria.
• Main recent public health genomics outcomes, strategies and 2011 trends
• Genetic/genomic vision of aging processes, as the decline of gene expression, according to the major breakthrough genomic studies
• Examples of new epigenetic programs in the field of anti-ageing, cosmetogenomics and beautyomics, also as the total integrative holistic programs – to evoke the genetic, physical and psychological potential of the person.

Special attention is paid to the difference between the speculation on genetic data and real mechanisms of genetically based prevention
Finally, the practical example in respect to all main genomic medicine and EBM criteria is demonstrated, including the new unique dynamic genomic expertise – after and before application of genetically based recommendations with demonstration of the practical outcome in early prevention, personalized treatment and anti-ageing effects.